Treace Medical Concepts (TMCI) Common Equity (2020 - 2026)

Treace Medical Concepts (TMCI) has 7 years of Common Equity data on file, last reported at $77.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 26.72% year-over-year to $77.2 million; the trailing twelve-month figure through Mar 2026 stood at $77.2 million (down 26.72% YoY), and the FY2025 full-year result was $87.3 million, down 22.64% from the prior year.
• Common Equity for Q1 2026 stood at $77.2 million, down from $87.3 million in the prior quarter.
• Across five years, Common Equity topped out at $157.6 million in Q1 2023 and bottomed at $60.5 million in Q4 2022.
• The 5-year median for Common Equity is $104.9 million (2024), against an average of $104.6 million.
• Peak annual rise in Common Equity reached 12792.69% in 2022, while the deepest fall reached 36.12% in 2022.
• A 5-year view of Common Equity shows it stood at $60.5 million in 2022, then soared by 127.89% to $137.9 million in 2023, then retreated by 18.16% to $112.9 million in 2024, then dropped by 22.64% to $87.3 million in 2025, then fell by 11.61% to $77.2 million in 2026.
• The last three Common Equity figures came in at $77.2 million (Q1 2026), $87.3 million (Q4 2025), and $89.2 million (Q3 2025), per Business Quant data.

Peer Comparison